USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
LIPELLA PHARMACEUTICALS, INC.
Address:
5414 GUARINO RD
PITTSBURGH, PA
Phone:
N/A
URL:
N/A
EIN:
202388040
DUNS:
187190850
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $199,617.00 2
SBIR Phase II $1,749,282.00 2
STTR Phase I $740,688.00 1

Award List:

Intravesical Liposome Treatment for Interstitial Cystitis

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$99,617.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Interstitial cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It can be described as a chronic inflammatory condition of the bladder wall, characterized by urinary frequency and urgency, and severe suprapubic and/or pelvic pain.… More

Intravesical Liposome Treatment for Interstitial Cystitis

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Interstitial cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It can be described as a chronic inflammatory condition of the bladder wall, characterized by urinary frequency and urgency, and severe suprapubic and/or pelvic pain.… More

Bladder drug delivery using intravesical liposomes to treat overactive bladder

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Lipella Pharmaceutical Inc has been successful with development of intravesical liposome for painful bladder syndrome/Interstitial cystitis (PBS/IC). Through SBIR funding, Lipella has been successful in establishing the pre-clinical safety of its primary… More

Developing Intravesical Liposomes for Interstitial Cystitis

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$740,688.00
Agency:
HHS
Principal Investigator:
Research Institution:
WILLIAM BEAUMONT HOSPITAL
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): LP08 is a novel intravesical treatment for interstitial cystitis (IC), a poorly understood chronic disorder of unknown etiology consisting of irritative bladder symptoms and pelvic pain that dramatically affects quality of life. In IC/PBS, two distinct subtypes… More

Bladder drug delivery using intravesical liposomes to treat overactive bladder

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$999,282.00
Agency:
HHS
Principal Investigator:
Jonathan H. Kaufman – 412-901-0315
Abstract:
DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. has been funded by National Institutes of Health Small Business Innovation and Research (SBIR) grants to develop intravesical liposome nanoparticles to treat overactive bladder (OAB), interstitial cystitis/painful bladder syndrome… More